Canonical and non-canonical adenosinergic pathways

E Ferretti, A L Horenstein, C Canzonetta, F Costa, F Morandi

Research output: Contribution to journalReview article

Abstract

Adenosine (ADO) is an immunosuppressive molecule with multiple functions in different human organs. ADO is released through the concerted action of surface molecules endowed with enzymatic functions, that belong to two different adenosinergic pathways. The canonical pathway is started by CD39, that converts ATP to AMP. On the other hand, the non-canonical pathway metabolizes NAD+ to ADPR, through the action of CD38. The latter byproduct is then converted to AMP by CD203a/PC-1. Both pathways converge to CD73, that fully degrades AMP to the final product ADO. In this Review we take into account the most relevant finding regarding the expression of ectoenzymes belonging to both adenosinergic pathways in different cell types, including regulatory cell subsets and neoplastic cells. Moreover, we summarize the role of these molecules in different physiological and pathological settings. Finally, we discuss potential therapeutic application of specific inhibitors of ectoenzymes and/or ADO receptors.

Original languageEnglish
Number of pages6
JournalImmunology Letters
DOIs
Publication statusE-pub ahead of print - Mar 14 2018

Fingerprint

Adenosine Monophosphate
Adenosine
Purinergic P1 Receptors
Immunosuppressive Agents
NAD
Adenosine Triphosphate
Therapeutics

Cite this

Canonical and non-canonical adenosinergic pathways. / Ferretti, E; Horenstein, A L; Canzonetta, C; Costa, F; Morandi, F.

In: Immunology Letters, 14.03.2018.

Research output: Contribution to journalReview article

Ferretti, E ; Horenstein, A L ; Canzonetta, C ; Costa, F ; Morandi, F. / Canonical and non-canonical adenosinergic pathways. In: Immunology Letters. 2018.
@article{7d5f6a5f817c45b3ac810bab438ac0f1,
title = "Canonical and non-canonical adenosinergic pathways",
abstract = "Adenosine (ADO) is an immunosuppressive molecule with multiple functions in different human organs. ADO is released through the concerted action of surface molecules endowed with enzymatic functions, that belong to two different adenosinergic pathways. The canonical pathway is started by CD39, that converts ATP to AMP. On the other hand, the non-canonical pathway metabolizes NAD+ to ADPR, through the action of CD38. The latter byproduct is then converted to AMP by CD203a/PC-1. Both pathways converge to CD73, that fully degrades AMP to the final product ADO. In this Review we take into account the most relevant finding regarding the expression of ectoenzymes belonging to both adenosinergic pathways in different cell types, including regulatory cell subsets and neoplastic cells. Moreover, we summarize the role of these molecules in different physiological and pathological settings. Finally, we discuss potential therapeutic application of specific inhibitors of ectoenzymes and/or ADO receptors.",
author = "E Ferretti and Horenstein, {A L} and C Canzonetta and F Costa and F Morandi",
note = "Copyright {\circledC} 2018 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.",
year = "2018",
month = "3",
day = "14",
doi = "10.1016/j.imlet.2018.03.007",
language = "English",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",

}

TY - JOUR

T1 - Canonical and non-canonical adenosinergic pathways

AU - Ferretti, E

AU - Horenstein, A L

AU - Canzonetta, C

AU - Costa, F

AU - Morandi, F

N1 - Copyright © 2018 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

PY - 2018/3/14

Y1 - 2018/3/14

N2 - Adenosine (ADO) is an immunosuppressive molecule with multiple functions in different human organs. ADO is released through the concerted action of surface molecules endowed with enzymatic functions, that belong to two different adenosinergic pathways. The canonical pathway is started by CD39, that converts ATP to AMP. On the other hand, the non-canonical pathway metabolizes NAD+ to ADPR, through the action of CD38. The latter byproduct is then converted to AMP by CD203a/PC-1. Both pathways converge to CD73, that fully degrades AMP to the final product ADO. In this Review we take into account the most relevant finding regarding the expression of ectoenzymes belonging to both adenosinergic pathways in different cell types, including regulatory cell subsets and neoplastic cells. Moreover, we summarize the role of these molecules in different physiological and pathological settings. Finally, we discuss potential therapeutic application of specific inhibitors of ectoenzymes and/or ADO receptors.

AB - Adenosine (ADO) is an immunosuppressive molecule with multiple functions in different human organs. ADO is released through the concerted action of surface molecules endowed with enzymatic functions, that belong to two different adenosinergic pathways. The canonical pathway is started by CD39, that converts ATP to AMP. On the other hand, the non-canonical pathway metabolizes NAD+ to ADPR, through the action of CD38. The latter byproduct is then converted to AMP by CD203a/PC-1. Both pathways converge to CD73, that fully degrades AMP to the final product ADO. In this Review we take into account the most relevant finding regarding the expression of ectoenzymes belonging to both adenosinergic pathways in different cell types, including regulatory cell subsets and neoplastic cells. Moreover, we summarize the role of these molecules in different physiological and pathological settings. Finally, we discuss potential therapeutic application of specific inhibitors of ectoenzymes and/or ADO receptors.

U2 - 10.1016/j.imlet.2018.03.007

DO - 10.1016/j.imlet.2018.03.007

M3 - Review article

C2 - 29550257

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

ER -